Polatuzumab Vedotin

Category: Cancer

Polatuzumab Vedotin Overview

Polatuzumab vedotin (INN;[1] brand name Polivy; development codes DCDS4501A and RG7596) is an antibody-drug conjugate or ADC designed for the treatment of cancer.[2] The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.[3] The drug was developed by Genentech and Roche. Polatuzumab vedotin contains a humanized monoclo...

Read more Polatuzumab Vedotin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Polatuzumab_vedotin

Recent Polatuzumab Vedotin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Polatuzumab Vedotin

Injection: 140mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Polatuzumab Vedotin or a similar ingredient: (1 result)

POLIVY Polatuzumab Vedotin-piiq